Skip to content
Screener

Baxter International BAX Front Line Care — Net Sales

Other product segments

Infusion Therapies & Technologies
$981M-1.3%
Care & Connectivity Solutions
$435M+1.9%
Drug Compounding
$320M+30.1%
Advanced Surgery
$304M+13.4%
Injectables & Anesthesia
$301M-10.1%

Similar metrics at other companies

Medline, Inc. logo
MDLNFront Line Care — Net Sales
$1.65B+3.8%
Energizer Holdings logo
ENRAuto Care — Net Sales
$170.1M-2.7%
Scotts Miracle-Gro logo
SMGLawn care — Net Sales
$265.2M-1.6%
Nature's Sunshine Products logo
NATRPersonal care — Net Sales
$6.76M+27.4%
Perrigo Company logo
PRGOSelf Care — Net Sales
$576.6M-3.7%
Kenvue logo
KVUESelf Care — Net Sales
$1.59B+2.2%

Other financials

Income statement

See full
Revenue$2.7B+2.9%
Gross profit$891.0M+3.5%
Operating income$66.0M+13.8%
Net income-$15.0M-112%
EPS (diluted)-$0.03-112%

Balance sheet

See full
Cash & equivalents$2.0B-12.1%
Total debt$224.0M-8.9%
Total equity$6.0B-14.7%
Total assets$19.8B-6.8%

Cash flow

See full
Operating cash flow$213.0M+210%
CapEx$128.3M+15.0%
Free cash flow$83.0M-42.1%

Valuation

See full
Market cap$14.13B+22.3%
Enterprise value$12.33B+22.1%
P/S1.3×+0.2×

Profitability

See full
Gross margin30.1%-5.9pp
Operating margin-2.7%
Net margin-9.7%+62.5pp
FCF margin3%-2.4pp

Returns & leverage

See full
Return on equity-16.7%-76.7pp
Debt / equity0.0×
Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Baxter International’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:50 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028962
(in millions)Three Months Ended March 31, 2026 / U.S.Three Months Ended March 31, 2026 / InternationalThree Months Ended March 31, 2026 / TotalThree Months Ended March 31, 2025 / U.S.Three Months Ended March 31, 2025 / InternationalThree Months Ended March 31, 2025 / Total
Advanced Surgery165139304145123268
Medical Products & Therapies6915941,2857295331,262
Care & Connectivity Solutions315120435316111427
Front Line Care1987227020275277
Healthcare Systems & Technologies513192705518186704
Injectables & Anesthesia180121301195140335
Drug Compounding320320246246
Pharmaceuticals180441621195386581

Item 1. Financial Statements (unaudited)

FAQ

What is Baxter International's front line care — net sales?
Baxter International (BAX) reported front line care — net sales of $270M in Q1 2026.
How has Baxter International's front line care — net sales changed year-over-year?
Baxter International's front line care — net sales decreased by 2.5% year-over-year, from $277M to $270M.
What is the long-term trend for Baxter International's front line care — net sales?
Over 4 years (2021 to 2025), Baxter International's front line care — net sales has grown at a 101.8% compound annual growth rate (CAGR), from $70M to $1.16B.
What does front line care — net sales mean?
This metric represents the total revenue generated by the Front Line Care business segment, which includes hospital-focused medical equipment and digital health solutions. It reflects the market demand and commercial success of products such as smart hospital beds and medical communication systems. This figure is a key indicator of the segment's contribution to the company's overall top-line performance.

Ask your AI about Baxter International's front line care — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude